Overview

This trial is active, not recruiting.

Condition chronic lymphocytic leukemia
Sponsor Celgene Corporation
Start date September 2009
End date January 2019
Trial size 1494 participants
Trial identifier NCT01081015, Connect™ CLL

Summary

The purpose of the Connect™ Chronic Lymphocytic Leukemia (CLL) Disease Registry is to explore the history and real world management of patients diagnosed with CLL, provide insight into the management of CLL, and evaluate the effectiveness of first, second and subsequent therapeutic strategies employed in both the community and academic settings.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective

Primary Outcomes

Measure
Identify and summarize patterns in therapeutic regimens and patient outcomes
time frame: up to 8 years

Secondary Outcomes

Measure
Summarize Effectiveness of Treatment Regimens
time frame: up to 8 years
Health Related Quality of Life Measures Related to Therapeutic Regimens
time frame: up to 8 years

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Clinical diagnosis with CLL - Clinical decision made to initiate first-line therapy, second-line therapy or subsequent line of therapy prior to enrollment into the ConnectTM CLL registry, but within 2 months of enrollment - Age≥18 years - Willing and able to provide signed informed consent - Willing and able to complete patient assessment questionnaires either alone or with minimal assistance from caregivers and/or trained site personnel Exclusion Criteria: - Participation in a clinical study in which study treatment is blinded - Patient condition is considered terminal (i.e.<6 months to live)

Additional Information

Official title Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Trial information was received from ClinicalTrials.gov and was last updated in August 2016.
Information provided to ClinicalTrials.gov by Celgene Corporation.